Myogem receives the Seal of Excellence from the European Commission under the H2020 SME Instrument Phase 1 research program for its project “New food for special medical purposes for the dietary management of Myotonic Dystrophy type 1.”
Myogem receives the Seal of Excellence.
MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.
Buy now¿Do you have any questions
or need more information?
Fill out the form and our team will respond as soon as possible.
Related news.
Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.
View report
Ver másDoctoral thesis
Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****
Ver másScientific article compiling the most recent drug development projects currently in the preclinical and clinical phases
View report
Ver más